Loading…
Aytu Biopharma received a warning for false and misleading sponsored link advertisements for ADZENYS XR-ODT (amphetamine), a Schedule II controlled substance used to treat ADHD, which violated the Federal Food, Drug, and Cosmetic Act by misbranding the drug. The promotional communications created a misleading impression about the safety and efficacy of the medication despite its boxed warning for high abuse potential, risk of overdose, death, and substance use disorder. The FDA determined these violations were particularly concerning from a public health perspective given the serious safety risks associated with this controlled substance.